Impax Laboratories Inc.(IPXL: Quote) said it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, via. Global Pharmaceuticals, Impax's generics unit.
In June 2010, Impax inked a deal with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle U.S. patent litigation concerning the production and sale of its Oxymorphone Hydrochloride Extended-Release Tablets approved by the U.S. Food and Drug Administration as therapeutically equivalent to the original formulation of OPANA ER. According to the settlement, Endo agreed to grant Impax a license to sell Impax's approved product on January 1, 2013.
Impax also noted that it is actively participating in efforts to support prescriber and patient education of this product through the FDA-approved Risk Evaluation and Mitigation Strategy. Oxymorphone Hydrochloride Extended-Release Tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.
Click here to receive FREE breaking news email alerts for Impax Laboratories Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org